Oncogenic potential of the adenovirus E4orf6 protein.

Por Moore, M, Horikoshi, N, Shenk, T
Publicado em 1996

A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.

Por Adachi, I., Watanabe, T., Takashima, S., Narabayashi, M., Horikoshi, N., Aoyama, H., Taguchi, T.
Publicado em 1996

Direct interaction between adenovirus E1A protein and the TATA box binding transcription factor IID.

Por Horikoshi, N, Maguire, K, Kralli, A, Maldonado, E, Reinberg, D, Weinmann, R
Publicado em 1991

Adenovirus E1A proteins interact with the cellular YY1 transcription factor.

Por Lewis, B A, Tullis, G, Seto, E, Horikoshi, N, Weinmann, R, Shenk, T
Publicado em 1995

Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression.

Por Horikoshi, N, Usheva, A, Chen, J, Levine, A J, Weinmann, R, Shenk, T
Publicado em 1995

Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma

Por Ohtsu, A, Baba, H, Sakata, Y, Mitachi, Y, Horikoshi, N, Sugimachi, K, Taguchi, T
Publicado em 2000

Wild-type p53 binds to the TATA-binding protein and represses transcription.

Por Seto, E, Usheva, A, Zambetti, G P, Momand, J, Horikoshi, N, Weinmann, R, Levine, A J, Shenk, T
Publicado em 1992